{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7"},{"groupId":"OG001","value":"99.4"}]}],"title":"All Treatment-Emergent Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0"},{"groupId":"OG001","value":"29.9"}]}],"title":"Serious Treatment-Emergent Adverse Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"311"}],"units":"Participants"}],"description":"Adverse Events to be measured are Treatment-Emergent and Serious AEs that occurred on or after first dose of investigational product and up to 28 days after the last dose","groups":[{"description":"neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m\\^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.","id":"OG000","title":"Neratinib Plus Capecitabine"},{"description":"lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m\\^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.","id":"OG001","title":"Lapatinib Plus Capecitabine"}],"paramType":"NUMBER","populationDescription":"Safety population: Participants receiving at least 1 dose of investigational product.","reportingStatus":"POSTED","timeFrame":"From first dose through last dose + 28 days, up to 41 months. The result is based on final data cut.","title":"Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}